Literature DB >> 15371927

Bacillus Calmette-Guérin-induced granulomatous hepatitis in a patient with a superficial bladder carcinoma.

Steven M Van Outryve1, Sven M Francque, Paul A Gentens, Filip F De Pauw, Erika Van den Bogaert, Eric A Van Marck, Paul A Pelckmans, Peter P Michielsen.   

Abstract

A 71-year-old male patient with a superficial transitional cell carcinoma of the urinary bladder developed high fever and jaundice, accompanied by progressively increasing serum aminotransferase activities, 2 weeks after the fourth local instillation with an attenuated live strain of Mycobacterium bovis [bacillus Calmette-Guérin (BCG)]. A liver biopsy showed non-caseating granulomatous hepatitis. Cultures for mycobacteria were negative. Mycobacterial DNA was not detected in liver tissue using the polymerase chain reaction. Empirical treatment with rifampicin and isoniazid was started, resulting in partial recovery. After 6 months of therapy, however, serum aminotransferase activities were still twice the upper limit of normal. A second liver biopsy still demonstrated several granulomas. Only after addition of prednisolone, liver tests completely normalized. Also histologically the lesions improved dramatically. This suggests that the BCG hepatitis was at least partially caused by a hypersensitivity reaction. Our patient is the first reported case of BCG hepatitis with histological follow-up under therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15371927     DOI: 10.1097/00042737-200410000-00012

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  4 in total

1.  Multi-organ failure with atypical liver granulomas following intravesical Bacillus Calmette-Guerin instillation.

Authors:  Michail Kaklamanos; Georgia Hardavella; Rodoula Trigidou; Georgios Dionellis; Nikolaos Paissios; Nikolaos Koulouris; Constantin Goritsas
Journal:  World J Hepatol       Date:  2011-03-27

2.  Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer.

Authors:  Ana T Vilares; Cláudio Nunes Silva; Miguel Correia da Silva; Joel Sousa; Bárbara Viamonte; António J Madureira
Journal:  Radiol Case Rep       Date:  2022-05-06

Review 3.  Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

Authors:  María Asunción Pérez-Jacoiste Asín; Mario Fernández-Ruiz; Francisco López-Medrano; Carlos Lumbreras; Ángel Tejido; Rafael San Juan; Ana Arrebola-Pajares; Manuel Lizasoain; Santiago Prieto; José María Aguado
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

4.  Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with Bacillus Calmette-Guérin.

Authors:  Aliye Soylu; Ali T Ince; Hakan Polat; Nurgul Yasar; Aydin Ciltas; Selvinaz Ozkara; Ali I Tasci
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-04-15       Impact factor: 3.944

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.